Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice

Hepatology. 2014 Apr;59(4):1555-63. doi: 10.1002/hep.26915. Epub 2014 Feb 28.

Abstract

Cell types and mechanisms involved in type I interferon (IFN)-mediated anti-inflammatory effects are poorly understood. Upon injection of artificial double-stranded RNA (poly(I:C)), we observed severe liver damage in type I IFN-receptor (IFNAR) chain 1-deficient mice, but not in wild-type (WT) controls. Studying mice with conditional IFNAR ablations revealed that IFNAR triggering of myeloid cells is essential to protect mice from poly(I:C)-induced liver damage. Accordingly, in poly(I:C)-treated WT, but not IFNAR-deficient mice, monocytic myeloid-derived suppressor cells (MDSCs) were recruited to the liver. Comparing WT and IFNAR-deficient mice with animals deficient for the IFNAR on myeloid cells only revealed a direct IFNAR-dependent production of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA) that could be assigned to liver-infiltrating cells. Upon poly(I:C) treatment, IFNAR-deficient mice displayed both a severe lack of IL-1RA production and an increased production of proinflammatory IL-1β, indicating a severely imbalanced cytokine milieu in the liver in absence of a functional type I IFN system. Depletion of IL-1β or treatment with recombinant IL-1RA both rescued IFNAR-deficient mice from poly(I:C)-induced liver damage, directly linking the deregulated IL-1β and IL-1RA production to liver pathology.

Conclusion: Type I IFN signaling protects from severe liver damage by recruitment of monocytic MDSCs and maintaining a balance between IL-1β and IL-1RA production.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Chemical and Drug Induced Liver Injury / metabolism*
  • Chemical and Drug Induced Liver Injury / prevention & control*
  • Disease Models, Animal
  • Injections
  • Interferon Type I / metabolism*
  • Interleukin 1 Receptor Antagonist Protein / deficiency
  • Interleukin 1 Receptor Antagonist Protein / genetics
  • Interleukin 1 Receptor Antagonist Protein / metabolism*
  • Interleukin-1beta / metabolism
  • Liver / metabolism
  • Liver / pathology
  • Mice
  • Mice, Knockout
  • Myeloid Cells / metabolism*
  • Myeloid Cells / pathology
  • Phenotype
  • Poly I-C / administration & dosage
  • Poly I-C / adverse effects
  • Poly I-C / pharmacology
  • RNA, Double-Stranded / administration & dosage
  • RNA, Double-Stranded / adverse effects*
  • RNA, Double-Stranded / pharmacology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Il1rn protein, mouse
  • Interferon Type I
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • RNA, Double-Stranded
  • Poly I-C